Filing Details

Accession Number:
0001487371-21-000027
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-25 20:37:31
Reporting Period:
2021-01-21
Accepted Time:
2021-01-25 20:37:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1487371 Genmark Diagnostics Inc. GNMK Surgical & Medical Instruments & Apparatus (3841) 272053069
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1543884 Michael Gleeson 5964 La Place Court
Carlsbad CA 92008
Svp, Corp. Accounts No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-21 37,555 $0.00 384,724 No 4 M Direct
Common Stock Acquisiton 2021-01-21 27,115 $0.00 411,839 No 4 M Direct
Common Stock Acquisiton 2021-01-21 19,166 $0.00 431,005 No 4 M Direct
Common Stock Disposition 2021-01-25 33,027 $14.22 397,978 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Market Stock Units Disposition 2021-01-21 37,555 $0.00 37,555 $0.00
Common Stock Market Stock Units Disposition 2021-01-21 27,115 $0.00 27,115 $0.00
Common Stock Market Stock Units Disposition 2021-01-21 19,166 $0.00 19,166 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
8,333 No 4 M Direct
19,167 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 30,069 Indirect Michael William Gleeson 2012 Irrevocable Trust
Footnotes
  1. The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted market stock units.
  2. Mr. Gleeson is the trustee of the Michael William Gleeson 2012 Irrevocable Trust and has voting and dispositive power with respect to these shares. Mr. Gleeson disclaims beneficial ownership except to the extent of his pecuniary interest therein.
  3. The MSUs vested in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person was eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares on the Issuer's three-year total Shareholder return, as compared to the Nasdaq Composite Index.
  4. The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares on the Issuer's two-year total Shareholder return, as compared to the Nasdaq Composite Index.
  5. Represents the target number of shares which remain subject to the award.
  6. The MSUs vest in three equal installments, on each of December 31, 2020, December 31, 2021, and December 31, 2022; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares on the Issuer's one-year total Shareholder return, as compared to the Nasdaq Composite Index.